| [1] | Moncrieff J, Cohen D (2005) Rethinking models of psychotropic drug action. Psychother Psychosom 74: 145–153.
|
| [2] | Hyman SE, Nestler EJ (1996) Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 153: 151–162.
|
| [3] | Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122: 509–522.
|
| [4] | Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, et al. (2000) Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174–180.
|
| [5] | Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, et al. (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46: 1375–1387.
|
| [6] | Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, et al. (2004) Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: Effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61: 1271–1279.
|
| [7] | Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, et al. (2006) Altered serotonin 1A binding in major depression: A [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 59: 106–113.
|
| [8] | Reivich M, Amsterdam JD, Brunswick DJ, Shiue CY (2004) PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 82: 321–327.
|
| [9] | Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, et al. (1997) Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16: 162–173.
|
| [10] | Lowther S, De Paermentier F, Cheetham SC, Crompton MR, Katona CL, et al. (1997) 5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. J Affect Disord 42: 199–207.
|
| [11] | Matsubara S, Arora RC, Meltzer HY (1991) Serotonergic measures in suicide brain: 5-HT1A binding sites in frontal cortex of suicide victims. J Neural Transm Gen Sect 85: 181–194.
|
| [12] | Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ (2002) The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology (Berl) 163: 42–53.
|
| [13] | Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, et al. (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46: 212–220.
|
| [14] | Healy D (1999) The antidepressant era. New York: Harvard University Press. 336 p.
|
| [15] | Bourin M, Fiocco AJ, Clenet F (2001) How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16: 9–21.
|
| [16] | Moncrieff J (2001) Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189: 288–295.
|
| [17] | Imlah NW (1985) An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression. Br J Psychiatry 146: 515–519.
|
| [18] | Emrich HM, Vogt P, Herz A (1982) Possible antidepressive effects of opioids: Action of buprenorphine. Ann N Y Acad Sci 398: 108–112.
|
| [19] | Robinson DS, Alms DR, Shrotriya RC, Messina M, Wickramaratne P (1989) Serotonergic anxiolytics and treatment of depression. Psychopathology 22: Suppl 127–36.
|
| [20] | Rickels K, Gordon PE, Gansman DH, Weise CC, Pereira-Ogan JA, et al. (1970) Pemoline and methylphenidate in midly depressed outpatients. Clin Pharmacol Ther 11: 698–710.
|
| [21] | Robertson MM, Trimble MR (1982) Major tranquillisers used as antidepressants. A review. J Affect Disord 4: 173–193.
|
| [22] | Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM (2005) Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 59: 495–510.
|
| [23] | Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 161: 1256–1263.
|
| [24] | Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM (2003) Toward a neuropsychological theory of antidepressant drug action: Increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry 160: 990–992.
|
| [25] | Tranter R, Healy H, Cattell D, Healy D (2002) Functional effects of agents differentially selective to noradrenergic or serotonergic systems. Psychol Med 32: 517–524.
|
| [26] | Furlan PM, Kallan MJ, Have TT, Lucki I, Katz I (2004) SSRIs do not cause affective blunting in healthy elderly volunteers. Am J Geriatr Psychiatry 12: 323–330.
|
| [27] | Mayers AG, Baldwin DS (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol 20: 533–559.
|
| [28] | Deptula D, Pomara N (1990) Effects of antidepressants on human performance: A review. J Clin Psychopharmacol 10: 105–111.
|
| [29] | Herrmann WM, McDonald RJ (1978) A multidimensional test approach for the description of the CNS activity of drugs in human pharmacology. Pharmakopsychiatr Neuropsychopharmakol 11: 247–265.
|
| [30] | Patten SB (2004) The impact of antidepressant treatment on population health: Synthesis of data from two national data sources in Canada. Popul Health Metr 2: 9.
|
| [31] | Moncrieff J, Pomerleau J (2000) Trends in sickness benefits in Great Britain and the contribution of mental disorders. J Public Health Med 22: 59–67.
|
| [32] | Dewa CS, Hoch JS, Lin E, Paterson M, Goering P (2003) Pattern of antidepressant use and duration of depression-related absence from work. Br J Psychiatry 183: 507–513.
|
| [33] | Goldberg D, Privett M, Ustun B, Simon G, Linden M (1998) The effects of detection and treatment on the outcome of major depression in primary care: A naturalistic study in 15 cities. Br J Gen Pract 48: 1840–1844.
|
| [34] | Tuma TA (2000) Outcome of hospital-treated depression at 4.5 years. An elderly and a younger adult cohort compared. Br J Psychiatry 176: 224–228.
|
| [35] | Kennedy N, Abbott R, Paykel ES (2003) Remission and recurrence of depression in the maintenance era: Long-term outcome in a Cambridge cohort. Psychol Med 33: 827–838.
|
| [36] | Knegtering H, Eijck M, Huijsman A (1994) Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging 5: 192–199.
|
| [37] | Wingen M, Bothmer J, Langer S, Ramaekers JG (2005) Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: A crossover trial. J Clin Psychiatry 66: 436–443.
|
| [38] | Ramaekers JG (2003) Antidepressants and driver impairment: Empirical evidence from a standard on-the-road test. J Clin Psychiatry 64: 20–29.
|
| [39] | Ramaekers JG, Muntjewerff ND, O'Hanlon JF (1995) A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 39: 397–404.
|
| [40] | Robbe HW, O'Hanlon JF (1995) Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 5: 35–42.
|
| [41] | Raptopoulos P, McClelland GR, Jackson D (1989) The clinical pharmacology of paroxetine in healthy subjects. Acta Psychiatr Scand Suppl 350: 46–48.
|
| [42] | Breggin PR (2003) Fluvoxamine as a cause of stimulation, mania and aggression: A critical analysis of the FDA-approved label. Ethical Hum Sci Serv 4: 211–227.
|
| [43] | Beasley CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME (1991) Fluoxetine versus trazodone: Efficacy and activating-sedating effects. J Clin Psychiatry 52: 294–299.
|
| [44] | Beasley CM, Sayler ME, Weiss AM, Potvin JH (1992) Fluoxetine: Activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 12: 328–333.
|
| [45] | Leo RJ (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57: 449–454.
|
| [46] | Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002) The emperor's new drugs: An analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat 5: 23.
|
| [47] | Moncrieff J, Kirsch I (2005) Efficacy of antidepressants in adults. BMJ 331: 155–157.
|
| [48] | Fisher S, Greenberg RP (1993) How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 181: 345–350.
|
| [49] | Niklson IA, Reimitz PE, Sennef C (1997) Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull 33: 41–51.
|
| [50] | Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, et al. (2004) Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials 25: 119–142.
|
| [51] | Cohen D (2005) Clinical psychoparmacological trials: “Gold standard” or fool's gold? In: Kirk SA, editor. Mental disorders in the social environment: Critical perspectives. New York: Columbia University Press. pp. 347–367.
|
| [52] | Van Putten T, Marder SR (1987) Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48: (Suppl)13–19.
|
| [53] | Malhi GS, Parker GB, Greenwood J (2005) Structural and functional models of depression: From sub-types to substrates. Acta Psychiatr Scand 111: 94–105.
|
| [54] | Mirowsky J, Ross CE (2003) Social causes of psychological distress. Chicago: Aldine de Gruyter. 320 p.
|
| [55] | Pilgrim D, Bentall RP (1999) The medicalisation of misery: A critical realist analysis of the concept of depression. J Ment Health 8: 261–274.
|
| [56] | Lacasse JR, Leo J (2005) Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med 2: e392. doi: 10.1371/journal.pmed.0020392.
|
